Aerovate Therapeutics (Aerovate Therapeutics) Price-to-Tangible-Book : 6.31 (As of May. 18, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics Price-to-Tangible-Book?

As of today (2024-05-18), Aerovate Therapeutics's share price is $20.57. Aerovate Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $3.26. Hence, Aerovate Therapeutics's Price to Tangible Book Ratio of today is 6.31.

The historical rank and industry rank for Aerovate Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

AVTE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.67 Med: 2.99 Max: 9.08
Current: 6.31

During the past 5 years, Aerovate Therapeutics's highest Price to Tangible Book Ratio was 9.08. The lowest was 1.67. And the median was 2.99.

AVTE's Price-to-Tangible-Book is ranked worse than
79.36% of 1226 companies
in the Biotechnology industry
Industry Median: 2.85 vs AVTE: 6.31

A closely related ratio is called PB Ratio. As of today, Aerovate Therapeutics's share price is $20.57. Aerovate Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $3.26. Hence, Aerovate Therapeutics's P/B Ratio of today is 6.31.

Aerovate Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Aerovate Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerovate Therapeutics Price-to-Tangible-Book Chart

Aerovate Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

1.67

5.71

5.74

Aerovate Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial													4.43	3.34	2.99	5.74	9.08

Competitive Comparison of Aerovate Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Aerovate Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerovate Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's Price-to-Tangible-Book falls into.

Aerovate Therapeutics Price-to-Tangible-Book Calculation

Aerovate Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	20.57	/	3.258
	=	6.31

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Aerovate Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerovate Therapeutics (Aerovate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

930 Winter Street, Suite M-500, Waltham, MA, USA, 02451

Website

https://www.aerovatetx.com

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

Executives

Hunter Gillies	officer: Chief Medical Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Ralph Niven	officer: Chief Development Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Benjamin T Dake	officer: See Remarks	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Marinus Verwijs	officer: SENIOR VICE PRESIDENT, CMC	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes	director, officer: Chief Executive Officer	1365 MAIN STREET, WALTHAM MA 02451
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot	officer: Chief Commercial Officer	AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel	director	4362 24TH STREET, SAN FRANCISCO CA 94114
George A Eldridge	officer: See Remarks	C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Allison Dorval	director	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Maha Katabi	director, 10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116